Literature DB >> 12963845

The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells.

Hannah Wingate1, Isabelle Bedrosian, Said Akli, Khandan Keyomarsi.   

Abstract

Cyclin E in complex with CDK2 is a positive regulator of the G1 to S phase transition of the cell cycle and is responsible for cells passing the restriction point, committing the cell to another round of cell division. Cyclin E is overexpressed and proteolytically cleaved into low molecular weight (LMW) isoforms in breast cancer cell lines and tumor tissues compared to normal cells and tissues. These alterations in cyclin E are linked to poor prognosis in breast cancer patients. In order to evaluate the biological effects of the LMW cyclin E, immortalized mammary epithelial cells, 76NE6, were stably transfected with each of the three cyclin E constructs. Our results reveal that the LMW forms of cyclin E (T1 and T2) are biologically functional, as their overexpression in the immortalized cells increases the ability of these cells to enter S and G2/M phase by 2 fold over full length or vector-alone transfected cells, concomitant with an increased rate of cell proliferation. In addition, these LMW isoforms are biochemically hyperactive, shown by their ability to phosphorylate substrates such as histone H1 4 fold more in cells transfected with T1 or T2 versus cells transfected with the full length form. These results suggest that overexpression of the LMW forms of cyclin E is mitogenic, stimulating the cells to progress through the cell cycle much more efficiently than the full length cyclin E.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963845

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  17 in total

Review 1.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

2.  Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

Authors:  Kelly K Hunt; Khandan Keyomarsi; Cansu Karakas; Min Jin Ha; Anna Biernacka; Min Yi; Aysegul A Sahin; Opoku Adjapong; Gabriel N Hortobagyi; Melissa Bondy; Patricia Thompson; Kwok Leung Cheung; Ian O Ellis; Sarah Bacus; W Fraser Symmans; Kim-Anh Do
Journal:  Clin Cancer Res       Date:  2016-11-23       Impact factor: 12.531

3.  Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.

Authors:  Said Akli; Tuyen Bui; Hannah Wingate; Anna Biernacka; Stacy Moulder; Susan L Tucker; Kelly K Hunt; Khandan Keyomarsi
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

4.  Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.

Authors:  Mylinh T Duong; Said Akli; Sira Macalou; Anna Biernacka; Bisrat G Debeb; Min Yi; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2013-08-16       Impact factor: 12.701

5.  Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.

Authors:  Said Akli; Carolyn S Van Pelt; Tuyen Bui; Laurent Meijer; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2011-03-08       Impact factor: 12.701

6.  Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.

Authors:  Joseph A Caruso; Rody Campana; Caimiao Wei; Chun-Hui Su; Amanda M Hanks; William G Bornmann; Khandan Keyomarsi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

8.  A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels.

Authors:  Christine M Stellrecht; Mary Ayres; Rishi Arya; Varsha Gandhi
Journal:  Breast Cancer Res Treat       Date:  2009-07-30       Impact factor: 4.872

9.  Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation.

Authors:  Nikki A Delk; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

10.  EVI1 splice variants modulate functional responses in ovarian cancer cells.

Authors:  Punashi Dutta; Tuyen Bui; Kyle A Bauckman; Khandan Keyomarsi; Gordon B Mills; Meera Nanjundan
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.